We evaluated inflammation at the small joints of feet in psoriasis patients without clinical
arthritis (PsO) as against clinically overt psoriatic arthritis (PsA) patients, using a low field …

To evaluate the effect of the phosphodiesterase 4 inhibitor apremilast in biologic-naïve
patients with early peripheral PsA in terms of disease activity, clinical manifestations, patient …

Patients with psoriatic arthritis (PsA) are suffering from a decreased quality of life despite
currently available treatments. In the latest years, novel therapies targeting the IL-17/IL-23 …

Objectives To determine the effects of biological disease-modifying anti-rheumatic drugs
(bDMARDs) on the quality of life (QoL) among patients with psoriatic arthritis (PsA). Design …

Objective Our objective was to assess the effectiveness of conventional and targeted
disease-modifying antirheumatic drugs (cDMARDs and tDMARDs, respectively) in treating …

Background Many patients with rheumatoid arthritis (RA) do not attain remission/low disease
activity, remaining in a moderate disease activity state (MDAS) with ongoing disability and …

Objective Deucravacitinib, a tyrosine kinase 2 inhibitor, was assessed in a phase 2 trial in
patients with active psoriatic arthritis (PsA). Here, we report effects of deucravacitinib from …

Purpose Psoriasis is a chronic, inflammatory, immune-mediated skin disease that has
significant impact on a patient's quality of life, yet it remains challenging for dermatologists to …

Objective Psoriatic arthritis (PsA) is chronic disease that compromises multiple domains and
might be associated with progressive joint damage, increased mortality, functional limitation …

Background Tofacitinib is an oral Janus kinase inhibitor for the treatment of psoriatic arthritis
(PsA). This post-hoc analysis of two phase III studies in patients with PsA treated with …